Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Product/Service, Trade Show

OurCrowd Showcases Israeli Tech at 2020 AIPAC Policy Conference

OurCrowd, the global crowdfunding venture investing platform and Israel's most active venture investor, will showcase select hightech companies from its portfolio of over 200 startups from Israel and around the globe at this year's AIPAC Policy Conference. Companies attending span a range of markets including MedTech, Artificial Intelligence, Mobility, Emergency Response, Foodtech, and more.

As Alan Dershowitz stressed at the Policy Conference several years ago, "There is no weapon more powerful in the fight [to defend Israel] than for Israel to develop technologies that the world cannot live without." "It is in this spirit," commented Alec Ellison, US Chairman of OurCrowd, "that we proudly showcase a sampling of Israeli companies impacting individuals' lives and entire industries."

OurCrowd Portfolio Companies on display at the OurCrowd Booth # 920 include:

OurCrowd Portfolio Companies & Funds presenting on the mainstage include:


Join OurCrowd U.S. Chairman Alec Ellison, also of AIPAC's National Venture/Tech Chairman at OurCrowd's booth in the AIPAC Village. For more information, contact Allison Spielman, allison@ourcrowd.com / (+1-917-741-9895)

To receive OurCrowd portfolio news updates, or to arrange interviews at the AIPAC Policy Conference with company CEOs, or OurCrowd U.S. Chairman Alec Ellison, contact Leah Stern at leah@ourcrowd.com (+44 747-0196-826)


About OurCrowd: OurCrowd is a global venture investing platform that empowers institutions and individuals to invest and engage in emerging companies. The most active venture investor in Israel, OurCrowd vets and selects companies, invests its capital, and provides its global network with unparalleled access to co-invest and contribute connections, talent and deal flow. OurCrowd builds value for its portfolio companies throughout their lifecycles, providing mentorship, recruiting industry advisors, navigating follow-on rounds and creating growth opportunities through its network of multinational partnerships. With $1.4 billion of committed funding, and investments in 200 portfolio companies and 20 venture funds, OurCrowd offers access to its membership of 40,000 individual accredited and institutional investors, family offices, and venture capital partners from over 183 countries to invest alongside, at the same terms. OurCrowd's portfolio is diversified across sectors and stages, ranging from seed and series A through late stage and pre-IPO firms. Since its founding in 2013, OurCrowd portfolio companies have been acquired by some of the most prestigious brands in the world, including Uber, Canon, Oracle, Nike, and Intel. To register and get involved, visit www.ourcrowd.com.

For Press Materials: http://blog.ourcrowd.com/aipac2020/

These press releases may also interest you

at 07:05
LifeMax Laboratories, Inc. ("LifeMax"), a private company focused on treating orphan diseases that have few or no therapeutic options, today announced the formation of AmMax Bio, Inc. ("AmMax") and an exclusive worldwide license from Amgen for the...

at 07:05
AstraZeneca today announced that IMFINZI® (durvalumab) has been approved in the US as a 1st-line treatment for adult patients with extensive-stage small cell lung cancer (ES-SCLC) in combination with standard-of-care (SoC) chemotherapies, etoposide...

at 07:05
ElevateBio, LLC, a Cambridge-based creator and operator of a portfolio of innovative cell and gene therapy companies, today announced it has closed a $170-million Series B financing that will support and accelerate the company's next phase of growth....

at 07:05
Generation Bio and Vir Biotechnology today announced a collaborative research agreement to explore the potential for Generation Bio's non-viral gene therapy platform to extend the impact and reach of Vir's current or future human monoclonal...

at 07:05
Compass Therapeutics, a clinical-stage biotechnology company focused on drugging the human immune synapse, today announced the publication of extensive data demonstrating the preclinical efficacy and safety of the company's lead investigational...

at 07:05
Seres Therapeutics, Inc., announced today that the Company has completed enrollment of its SER-109 Phase 3 clinical study, ECOSPOR III. SER-109 is an oral, first-in-field microbiome therapeutic candidate that has been granted Orphan Drug and...

News published on 27 february 2020 at 10:05 and distributed by: